Chemotherapy Induced Anemia Treatment Market Size in the 7MM is expected to grow by 2032, estimates DelveInsight

DelveInsight's 'Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Chemotherapy Induced Anemia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Unlock key insights into the Chemotherapy-Induced Anemia Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chemotherapy Induced Anemia Market Size- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chemotherapy Induced Anemia Market Report
• According to DelveInsight's analysis, in Spain study of 349 patients with lung cancer, 64 already had anemia before starting chemotherapy. Among the 285 patients with normal hemoglobin (Hb) levels at baseline, 80.7% (n = 230) developed anemia. Of these, 49.1% experienced mild anemia, 25.6% had moderate anemia, and 6% suffered from severe anemia.
• Our analysis reveals that in the US around 90% of non-Hodgkin lymphoma patients develop CIA during their first chemotherapy cycle. The incidence proportions for CIA grades were 58.9%, 28.2%, 11.2%, and 1.8% for grades 1, 2, 3, and 4, respectively. In terms of morphology, 90% of CIAs were normocytic, 6% were macrocytic, and 4% were microcytic, with 53% being normochromic, 41% hyperchromic, and 6% hypochromic.
• The leading Chemotherapy Induced Anemia Companies such as Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus, Cadila and others.
• Promising Chemotherapy Induced Anemia Therapies such as Roxadustat, Desidustat, SEPO®, Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib, and others

Stay ahead in the competitive landscape of the Chemotherapy Induced Anemia Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chemotherapy Induced Anemia Treatment Market Size- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy Induced Anemia Epidemiology Segmentation in the 7MM
• Chemotherapy Induced Anemia Incident Cases
• Chemotherapy Induced Anemia Severity-Specific Incident Cases
• Chemotherapy Induced Anemia Treatable Cases

Download the report to understand which factors are driving Chemotherapy Induced Anemia epidemiology trends @ Chemotherapy Induced Anemia Prevalence- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy Induced Anemia Emerging Drugs
Roxadustat (FG-4592), an oral medication, is the first in a new class of medicines comprising hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat has been approved in European Union (EU) member states, including the European Economic Area (EEA) countries, as well as in Japan, China, Chile, and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). The drug has completed its evaluation in Phase II in patients with Chemotherapy Induced Anemia. Roxadustat is also in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS).

Chemotherapy Induced Anemia Therapeutics Market
"The current market for CIA remains underdeveloped, with a lack of new drugs and limited approved therapies. This gap has made biosimilar a key driver of market expansion, offering affordable alternatives to existing medications. As new drug development remains slow, biosimilar are increasingly filling the void, providing accessible treatment options and contributing to market growth by reducing costs for both healthcare providers and patients."

Chemotherapy Induced Anemia Treatment Market
Anemia is a frequent but insidious complication of cancer and its cytotoxic chemotherapy. According to the World Health Organization (WHO) definition, anemia occurs when hemoglobin (Hb) levels drop below 12 g/dL for women and 13 g/dL for men, and severity ranges from mild to severe or life-threatening. Anemia contributes to debilitating fatigue, lethargy, cardiovascular problems, shortness of breath, and reduced cognitive function in individuals who often already have significant morbidity and diminished quality of life (QOL) due to their malignancy.

Discover the future of Chemotherapy Induced Anemia treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Chemotherapy Induced Anemia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chemotherapy Induced Anemia Market Report
• Coverage- 7MM
• Forecast Period- 2023-2032
• Chemotherapy Induced Anemia Companies- Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus, Cadila and others.
• Chemotherapy Induced Anemia Therapies- Roxadustat, Desidustat, SEPO®, Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib, and others
• Chemotherapy Induced Anemia Therapeutic Assessment: Chemotherapy Induced Anemia Current Marketed and Chemotherapy Induced Anemia Emerging Therapies
• Chemotherapy Induced Anemia Market Dynamics: Chemotherapy Induced Anemia market drivers and Chemotherapy Induced Anemia market barriers
• Chemotherapy Induced Anemia Unmet Needs, KOL's views, Analyst's views, Chemotherapy Induced Anemia Market Access and Reimbursement

Explore the dynamics of the Chemotherapy Induced Anemia Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chemotherapy Induced Anemia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Chemotherapy Induced Anemia Overview at a Glance
4. Chemotherapy Induced Anemia Overview at a Glance
5. Chemotherapy Induced Anemia Executive Summary
6. Disease Background and Overview
7. Chemotherapy Induced Anemia Epidemiology and Patient Population
8. Japan
9. Patient Journey
10. Chemotherapy Induced Anemia Emerging Drugs
11. Other Assets
12. Chemotherapy Induced Anemia: 7 Major Market Analysis
13. Chemotherapy Induced Anemia KOL Views
14. Chemotherapy Induced Anemia SWOT
15. Chemotherapy Induced Anemia Unmet Needs
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.